Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

INDP

INDP News

Newswire

08:02

Indaptus Therapeutics' Chief Scientific Officer to Present at Donor Selection & Cell Source Summit, Highlighting Decoy Bacteria Platform for Allogeneic Immune Cell Cancer Therapy.

17:51

Indaptus shares surge 11.95% after hours as Maxim Group analyst maintains Buy rating, citing moderate buy consensus.

20:24

Indaptus Therapeutics (INDP) Pauses Clinical Trial Enrollment Amid Mixed Results

19:55

Indaptus shares jump 10.38% after hours on $2.3M fundraising and positive Decoy20 safety data in Q3 results.

11:09

Indaptus shares surge 13.79% intraday after positive safety data in Decoy20 trial and $2.3M fundraising.

View More

About INDP

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More